approximately 30 % of AML patients, implicating FLT3 as a driver of the disease and therefore as a target for therapy. We report the characterization of AC220, a second generation FLT3 inhibitor, and a comparison of AC220 to the first generation FLT3 inhibitors CEP-701, MLN-518, PKC-412, sorafenib and sunitinib. AC220 exhibits low nanomolar potency in biochemical and cellular assays, exceptional kinase selectivity, and in animal models is efficacious at doses as low as 1 mg/kg given orally once daily. The data reveal that the combination of excellent potency, selectivity and pharmacokinetic properties is unique to AC220, which therefore is the first drug candidate with a profile that matches the characteristics desirable for a clinical FLT3 inhibitor.
inhibitory activity, however, they were not expressly developed or optimized as FLT3
inhibitors. [38] [39] [40] [41] [42] To fully explore the potential of FLT3 inhibition as AML therapy, and to determine whether FLT3 inhibition is sufficient to yield a therapeutic benefit 26 , may require a second generation inhibitor that has been expressly optimized to inhibit FLT3
with very high potency and to be highly selective against other kinases, together with pharmacokinetic properties that afford complete and sustained inhibition of FLT3 in patients' leukemic blast cells.
AC220 is a novel compound expressly optimized as a FLT3 inhibitor for the treatment of AML. We show here that AC220 inhibits FLT3 with low nanomolar potency in cellular assays and is highly selective when screened against the majority of the human protein kinome. We further demonstrate that the combination of high potency and selectivity exhibited by AC220 is unique compared to CEP-701, PKC-412, MLN-518, sunitinib and sorafenib. AC220 inhibits FLT3 activity in vivo, significantly extends survival in a mouse model of FLT3-ITD AML at doses as low as 1 mg/kg when dosed orally once a day, eradicates tumors in a FLT3-dependent mouse xenograft model at 10 mg/kg, and potently inhibits FLT3 activity in primary patient cells. The results presented
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Methods
Compounds MLN-518 was custom synthesized by CiVentiChem (Cary, NC), and sunitinib was custom synthesized by Sai Advantium, Ltd. (Hyderabad, India). Sorafenib, PKC-412, CGP-52421, CEP-701 and AC220 were synthesized at Ambit Biosciences.
Biochemical kinase binding assays
KinomeScan kinase binding assays were performed as previously described. 43, 44 For the 
Cellular assays
MV4-11 and RS4;11 cells were cultured in Iscove's media with 10 % FBS and RPMI complete with 10 % FBS, respectively. For proliferation assays, cells were cultured overnight in low serum media (0.5 % FBS), then seeded in a 96-well plate at 40,000 cells per well. Inhibitors were added to the cells and incubated at 37 °C for 72 hours for MV4-11 and 48 hours for RS4;11 cells. Cell viability was measured using the Cell Titer-Blue
Cell Viability Assay from Promega (Madison, WI). To measure inhibition of FLT3
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From -7 -taken semi-longitudinally using three groups of three animals each, taking two to three timepoints per animal to obtain a total of three independent plasma concentration timecourses. Plasma samples and controls (25 µL) were extracted with four volumes of acetonitrile containing an internal standard and analyzed by LC/MS/MS. 
Animal efficacy studies

Subcutaneous xenograft model
This model was performed at Ambit to measure in vivo inhibition of FLT3, and by Piedmont Research Center LLC (Morrisville, NC) to determine anti-tumor efficacy, following published procedures. 20 Compounds were formulated and administered as described for pharmacokinetic studies above. To measure FLT3 inhibition, tumors were harvested at 2 or 24 hours after compound administration, weighed and lysed by 
Bone marrow engraftment model
The model was performed according to published procedures. 20 For intravenous bone marrow engraftment, NOD-SCID mice were acclimated for two weeks before pretreatment with 150 mg/kg cyclophosphamide (Sigma) delivered intraperitoneally once a day for two days. Following a 48 hour rest period, animals were given an intravenous injection of 5 x 10 6 MV4-11 cells into the tail vein. AC220 was formulated and delivered as described above for pharmacokinetic studies.
Primary cell assays
Leukemia cell specimens were provided by the Sidney Kimmel Cancer Center at the 
Results
Potency of FLT3 Inhibition
To identify promising starting points for kinase inibitor drug discovery we screened a scaffold-focused library of compounds against a panel of kinases. 46 Among the hits were compounds with binding affinity for FLT3 below 100 nanomolar and excellent kinase selectivity that also were drug-like and for which analogs to explore structure activity relationships could be secured by standard synthetic chemistry procedures. Optimization of the initial hits yielded AC220, a novel bis-aryl urea FLT3 inhibitor (Figure 1 ). The chemistry of optimization and structure activity relationships will be described in detail elsewhere (manuscript submitted).
To compare the potency of AC220 to that of other FLT3 inhibitors in clinical development we first used a previously described biochemical binding assay. 43 We included in this comparison CEP-701, MLN-518, PKC-412, sorafenib, sunitinib, as well as CGP-52421, a metabolite of PKC-412 that may be the major active species in patients ( Figure 1 ). 26 All compounds tested had high affinity for FLT3 in the binding assay (Table 1) , with sunitinib exhibiting the greatest potency, followed by AC220. To determine the ability of compounds to inhibit FLT3 in the cellular environment we measured inhibition of FLT3 autophosphorylation in the human leukemia cell lines MV4-11, which harbors a homozygous FLT3-ITD mutation and is FLT3-dependent 19,47 , and RS4;11, which expresses wild type FLT3. 48 AC220 was the most potent cellular FLT3-ITD inhibitor tested. MLN-518 and sunitinib, in contrast, were more than tenfold less potent in the cellular autophosphorylation assays compared to the binding assay, and consequently were, along with the PKC-412 metabolite CGP-52421, the least potent compounds in cells (Table 1) .
To determine the effect of FLT3-ITD inhibition on cell growth we measured MV4-11 cell proliferation in the presence of each FLT3 inhibitor. The IC 50 s in this assay tracked very well with FLT3 autophosphorylation inhibition, with AC220 and sorafenib
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From being the most potent compounds (Table 1) . One major exception was sunitinib, which inhibited MV4-11 cell proliferation with almost eightfold greater potency than it inhibited FLT3-ITD autophosphorylation. Inhibition of other targets by sunitinib, which is capable of interacting with a large number of kinases 44 , may be contributing to the effect on MV4-11 cell proliferation. As a cellular selectivity control we measured the effect on proliferation of A375 cells, which harbor an activating mutation in BRAF and are not FLT3-dependent. There was no evidence of inhibition of the growth of A375 cells by AC220 (Table 1) 
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These results establish that AC220 has strong activity against FLT3 in biochemical and cellular assays, is not generally cytotoxic, and is among the most potent FLT3 inhibitors known.
Kinase Selectivity
To assess the potential of AC220 to inhibit off-target kinases, and to compare its selectivity to that of the other FLT3 inhibitors, we screened the compounds against a The highest affinity target identified for AC220 was FLT3 (Supplementary Table   S1 ). The only other kinases with binding constants within tenfold that for FLT3 were the closely related receptor tyrosine kinases (RTKs) KIT, PDGFRA, PDGFRB, RET and CSF1R, and only four additional kinases, also related RTKs (FLT1, FLT4, DDR1, VEGFR2), bound with K d s within 100fold of that for FLT3. In follow-up cellular assays the activity of AC220 against KIT, RET, CSF1R and PDGFR was at least tenfold less potent than the cellular activity against FLT3, confirming the selectivity observed in the biochemical assays (data not shown). The kinase interaction pattern for AC220 was therefore highly focused ( Figure 2 ). In contrast, CEP-701, PKC-412, CGP-52421 and sunitinib crossreacted extensively with kinases of all groups and subfamilies, and even sorafenib had a substantially broader interaction pattern ( Figure 2 and Supplementary   Table S1 ). Broad interaction patterns have also previously been reported for NVP-AST487, ABT-869 and TKI-258. 44 The only compound among those tested that had a similar profile to AC220 was MLN-518, which also predominantly targeted class III RTKs ( Figure 2 and Supplementary Table S1 ). To quantitate the selectivity of each compound we calculated absolute selectivity scores as well as selectivity scores relative to FLT3 (Table 2) . 44 The absolute and the relative scores for AC220 and MLN-518 were comparable to each other, and lower than for the other compounds. They were in the same range as scores previously determined for other selective inhibitors such as imatinib and gefitinib. 44 PKC-412, CGP-52421 and CEP-701 are close analogs of staurosporine and their broad crossreactivity is therefore not surprising. These results show that AC220
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From is the only compound among those tested that is both highly potent as a FLT3 inhibitor in in vitro and cellular assays, and has a highly focused and selective interaction pattern across the human protein kinome. The biochemical profile of AC220 therefore is unique among the FLT3 inhibitors tested and closely matches the desirable profile for a clinical FLT3 inhibitor.
Pharmacokinetics
To assess the pharmacokinetic properties of AC220 a single dose of 10 mg/kg was administered to mice by oral gavage and plasma levels were measured over a 24 hour period ( Figure 3A and Table 3 ). The compound was well absorbed, achieving a maximum plasma level (C max ) of 3.8 µM (2,100 ng/mL) within two hours of dosing. The apparent plasma half-life was approximately four hours. The peak concentration of free AC220 (taking into account plasma protein binding of approximately 99 %; data not shown) after a single 10 mg/kg dose therefore is more than 30-fold above the IC 50 for FLT3-ITD inhibition in cellular assays. After 24 hours estimated free AC220 is still present at a concentration approximately at the cellular IC 50 , indicating that once a day oral dosing is sufficient for continuous inhibition of FLT3 activity in mice. To determine whether varying the dose of AC220 resulted in a corresponding change in plasma levels we measured single dose pharmacokinetics at doses ranging from 0.1 to 300 mg/kg ( Figure 3B and Table 3 ). Total exposure (AUC 0-24 hrs ) as well as C max correlated well with the administered dose between 0.1 and approximately 30 mg/kg. At higher doses both C max and AUC 0-24 hrs continued to increase, but approached a plateau above 100 mg/kg. The oral bioavailability of AC220, determined in rats by comparing oral and For personal use only. on August 31, 2017. by guest www.bloodjournal.org From intravenous pharmacokinetics at 3 mg/kg, was approximately 40 %. To ensure that the pharmacokinetic properties did not change with repeated dosing we administered AC220 to rats at 10 mg/kg orally once a day for five days, and measured plasma levels after the final dose. The concentration of AC220 in plasma was consistent following single and repeat dosing (data not shown). The pharmacokinetics of AC220 therefore are dose proportional in the dose range required for inhibition of FLT3, and appropriate plasma levels of AC220 can be maintained through repeat dosing.
To compare the pharmacokinetics of AC220 to those of other FLT3 inhibitors we measured plasma levels of CEP-701, MLN-518, PKC-412 and CGP-52421, sunitinib and sorafenib in mice after a single oral dose of 10 mg/kg ( Table 3 ). The C max and AUC 0-24 hrs for CEP-701, MLN-518, PKC-412 and sunitinib were five-to one hundredfold lower than for AC220. The peak free plasma concentration (taking into account mouse plasma 
In vivo efficacy in tumor models
To determine whether AC220 could inhibit FLT3 activity in vivo we used the FLT3-ITD- 
of tumors in all animals, and no tumor regrowth was observed during the 60 day post-treatment observation period ( Figure 4B ). There was no weight loss or any other obvious signs of toxicity. At the end of the study all animals remained essentially tumor free. Treatment with sunitinib also caused tumors to shrink, but not as rapidly as with AC220, and tumor growth resumed immediately upon discontinuation of treatment in all but one of the animals ( Figure 4B ). There was also substantially more variability in the response of individual tumors than there was for AC220 ( Figure 4B ).
These results are consistent with previous observations with sunitinib in this model.
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Published results with sorafenib in the MV4-11 tumor xenograft model also show substantial activity with once a day oral dosing at 10 mg/kg, with complete regressions observed in nine of ten treated animals 17 , comparable to the activity of AC220 demonstrated here.
To determine whether AC220 is also efficacious in a more physiologically relevant context that mimics some of the pathology of human leukemia, we used a mouse bone marrow engraftment model where the tumor cells establish in the bone marrow and disseminate. 20 MV4-11 cells were injected into the tail vein of mice that had been previously treated with cyclophosphamide to ablate the bone marrow. After 23 days to allow the disease to establish, treatment was initiated with 0.1, 1, and 10 mg/kg AC220 or vehicle alone, using groups of five mice each. With once a day dosing at 10 mg/kg the free plasma concentration of AC220 should remain at or above the cellular IC 50 at all times during the entire treatment period, at 1 mg/kg it likely is below the cellular IC 50 during a substantial fraction of each 24 hour period, and at 0.1 mg/kg the free plasma concentration may only approach the cellular IC 50 briefly after each daily dose. AC220
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From -17 -was administered once a day orally for 30 days. No obvious toxicity or body weight loss was attributed to treatment with AC220. In the vehicle control group animals experienced hind limb paralysis, and the mean survival time was 49 days, with all animals expired by day 52 ( Figure 4C ). AC220 prolonged survival in a dose dependent manner. At 10 mg/kg, 80 % of animals treated survived until the study was terminated on day 172, 119 days after discontinuation of treatment, corresponding to at least a 250 % increase in life span (ILS) (p < 0.00001). At the time the study was terminated the animals did not exhibit any signs of disease. At 1 mg/kg a significant increase in the mean survival time was observed, to 77 days (55 % ILS) (p = 0.0036). At the lowest dose tested of 0.1 mg/kg, a marginal 10 % ILS relative to vehicle was observed (p = 0.94). Together, these results clearly demonstrate that AC220 is efficacious in in vivo models of FLT3-dependent disease at very modest doses.
Activity in primary AML cells
To test whether AC220 has activity in primary cells we obtained peripheral blood blasts from a 55 year old male with relapsed acute myeloid leukemia. The blasts harbored a 33 base pair FLT3-ITD mutation in the juxtamembrane domain. Cells were treated with AC220 for one hour, and the phosphorylation state of FLT3 determined by western blot and enzyme-linked immunoassay (ELISA) ( Figure 5A ). FLT3 autophosphorylation was inhibited with an IC 50 of 2 nM, comparable to the activity observed in the MV4-11 cell line (Table 1) . To determine the effect on blast cell survival we measured cell viability after exposure to AC220. The primary cells were sensitive to AC220 with an IC 50 of 0.3 nM ( Figure 5B) , again comparable to the activity observed in the MV4-11 cell line For personal use only. on August 31, 2017. by guest www.bloodjournal.org From (Table 1) . AC220 activity against blast cells from four additional patients harboring FLT3-ITD mutations was similar, with IC 50 s ranging from 0.8 to 2 nM ( Figure 5C ). The potency of AC220 in blasts observed here is comparable to or better than what has been reported for other FLT3 inhibitors in primary cells.
19,32,36,50 The fraction of cells sensitive to AC220 was variable among the samples tested, and a more comprehensive characterization of the effects of AC220 on primary cells will be published separately.
The present results do demonstrate that AC220 is a highly potent inhibitor of FLT3 in primary patient cells.
Discussion
The association of FLT3 mutations with poor clinical outcome We present here an initial characterization of the biochemical and pharmacological activity of the novel FLT3 inhibitor AC220. AC220 is unique among FLT3 inhibitors currently in development in that it combines high potency, excellent kinase selectivity and favorable pharmacokinetic properties. Among the compounds tested, only CEP-701 and sorafenib were comparably potent in cellular assays for FLT3 inhibition. CEP-701 is a non-selective staurosporine analog. Sorafenib is highly potent and also has pharmacokinetic properties in animals at least as favorable as AC220, but is not as selective. Sorafenib is known to inhibit kinases other than FLT3 and class III RTKs at clinical doses, and is not currently approved for treatment of AML, or for continuous dosing in patients. Only MLN-518 has kinase selectivity comparable to AC220, however MLN-518 is 30 to 100-fold less potent than AC220 in cellular assays.
In humans, both sorafenib and MLN-518 have been given with twice-a-day dosing schedules, and responses with MLN-518 generally have been transient. 23 ,31 AC220
therefore is a second generation FLT3 inhibitor that has been explicitly optimized for the combination of properties believed to be required for the successful treatment of AML, and specifically to test the hypothesis that selective FLT3 inhibition will result in clinical benefit. AC220 is being evaluated as a treatment for AML in clinical trials.
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